Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS' Verma Touts Value-Based Payments After Cancellation Of Pilot For Novartis' Kymriah

Executive Summary

'It's not for every medication,' CMS administrator says, but agency continues to explore how to apply value-based pricing.

You may also be interested in...



New Payment Models For Curative Treatments Have CMS’ Attention, Verma Says

US Centers for Medicare and Medicaid Services administrator Seema Verma discusses solutions for handling the high cost of gene therapy and the Trump administration’s drug pricing agenda in briefing with reporters.

Value-Based Contracting Bill Aims For Bipartisan Political Support

Legislation from Sens. Bill Cassidy and Mark Warner would eliminate barriers to value-based contracting for drugs reimbursed by public payers. 

HHS Message On Value-Based Drug Pricing Complicated But Themes Emerging

US government involvement in value assessments for prescription drugs and the benefits of outcomes-based contracting in lowering drug prices are among the issues being discussed.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS123485

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel